51 books like Bad Pharma

This classic work of history and investigative reporting reads like a whodunit. It’s about the ill-willed contrarians who tried to convince the public that scientists don’t know what they do know: that our planet is warming as a result of human actions.

So, the book is not at all about scientists’ ignorance but instead about an illusion of uncertainty that has been deliberately fabricated.

If Oreskes & Conway documented the historical trend, Michaels shows what the daily battle over the implications of science for governance is like from within. As former Assistant Secretary for Labor for OSHA, he recounts the never-ending combat over how science is generated and interpreted when it comes to the safety and comprehension of the American public. From dark money to hired guns to compromised scientists, he puts names and faces to the war on science, with truth as the first casualty.

I don’t often praise edited collections, but this book is the most clear-eyed discussion of our current predicament in the face of worsening global warming I have ever encountered. The authors argue that the political deployment of geoengineering to ‘save’ us has become essentially a foregone conclusion—forget all that wishful Green New Deal happy talk. They then proceed to argue out the various potential political scenarios concerning what this means for future politics. Read this and weep.

Edwards revealed how the very architecture of early computers owed a debt to the political structures of the Cold War. The innovation of a command/control/information infrastructure set the template for military regimentation, and subsequently for the surveillance society we currently inhabit. The story of how cybernetics—a field that never quite made the grade as pure science—nevertheless conquered the culture, is fascinating.

A gut-wrenching but provokingly beautiful story that highlights an illness that isn’t spoken much about in fiction.

The relationship between Stella and Will is such a heartbreakingly warming story that gives the reader a new-found understanding of how cystic fibrosis can impact an individual's life. I enjoy reading stories involving new, important conversations that need to be had, especially on topics we don’t often see in novels.

I think it’s important for writing to help spread awareness. It’s something that I myself want to do more in my own work. 

This account of the early years of Vertex Pharmaceuticals, from its inception as a scrappy start-up to its early work in HIV, is a must-read classic for anyone interested in how science turns into new drugs. Barry Werth’s journalistic play-by-play is a cinematic, true-to-life picture of the strategic decisions, real-world challenges, and larger-than-life personalities that underlie modern drug development. His riveting follow-up, The Antidote, continues the saga by taking readers through Vertex’s pathbreaking work to transform the care of patients with hepatitis C and cystic fibrosis.

I found, as a history buff, The Struggle for Drug Reform to be an eye-opener about how America’s exceptionally high drug prices among other deficits in health care quality and coverage resulted from the past exercise of power by the pharmaceutical industry, the lynchpin of America’s “medico-industrial complex.”

I was impressed by historian Tobbell’s meticulously researched account of the industry’s strategic alliances with self-interested medical scientists, not just conservative political forces, and its use of anti-communist propaganda to fight off the threat of drug pricing regulations.

I personally found important her discussions of how the industry allied with the American Medical Association against universal health care, against FDA demands for evidence about drug efficacy and safety before allowing drugs on the market, and against the threat to its profits from generic drugs. 

I find Angell’s The Truth About the Drug Companies extremely valuable for teaching students about how the pharmaceutical industry translates high profits into power resources to protect and increase those profits over time.

The former New England Journal of Medicine editor exposed how drug companies enlist politicians, the FDA, and medical academia for their cause. And armies of lawyers to extend monopoly marketing rights for years.

It was my first introduction to how they spend more on marketing than research, much of that on “copy-cat” drugs of dubious superiority to ones with expired patents.

As a tax (and high drug price) payer, I was disturbed to learn how they use government funds for basic research and then rig and spin their reporting of clinical studies to inflate their products’ therapeutic value and underplay their risks. 

Two pharmacists sit in a Boston courtroom accused of murder. The weapon: a fungus. The death count: 100 and rising. These facts set the stage for a true-crime thriller by investigative journalist Jason Dearen, and it has the makings of a horror movie. There’s scientific hubris, sketchy ethics, a cover-up, and a monster, too: a slimy, sticky, fungal mold that infected patients and began eating their brains alive. It’s riveting, packed with information about how fungal spores managed to contaminate a medical supply chain, and frankly hard to put down. I have done my share of forensic research, and never have I encountered killer fungus before; I consider this an unmissable book.

If you think that medical journals published by respected medical societies are full of good science, think again.

For me, Abramson’s Sickening nailed the case for a conclusion that the net effect of the many hundreds of medical journals published here and around the world is to subtract from the sum of human medical knowledge.

Abramson, as an expert witness in criminal and civil cases against drug companies, draws in part on subpoenaed documents to expose how medical science, as part of the entire medical-industrial complex, is corrupted from start to finish by the drug industry’s funding of most clinical trials, their control over the data analysis, and even their ghost-writing of articles submitted to journals.

New and disturbing was the withholding of clinical trials’ raw data from journals’ peer reviewers. Instead, they get biased summaries bearing drug manufacturers’ fingerprints.